Clinical Research, Pharma & Healthcare FinancingFDA Accepts sBLA for Genentech’s Gazyva in Lupus NephritisBusiness WireMarch 5, 2025August 1, 2025 by Business WireMarch 5, 2025August 1, 20250107 Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit The filing application is based...
